Bionovo Receives US Patent For Bezielle

Bionovo’s US Patent No 7,700,136 also covers the use of its proprietary Bezielle formulation as a monotherapy for the treatment of breast cancer. The patent is expected to provide coverage through at least November 13, 2026.

Bionovo claimed that Bezielle targets diseased cells while leaving normal cells healthy and intact. It stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain largely unharmed.

Isaac Cohen, chairman and CEO of Bionovo, said: “Following two positive Phase 1 trials of Bezielle, this is another critical milestone in Bionovo’s efforts to develop Bezielle into a valuable treatment option for an indication that needs new, safe treatment options. Furthermore, intellectual property protection is essential for successfully partnering our drug candidates, and further assuring shareholder value creation.”

Bionovo is a California-based pharmaceutical company focused on the discovery and development of safe and effective treatments for women’s health and cancer.

The patent issued is Bionovo’s second issued patent, with over 70 other patent applications currently pending. Bionovo’s first issued patent was US Patent No. 7,482,029, issued on January 27, 2009. The patent covers treatment of hot flashes with MF101 (Menerba), which has been demonstrated in clinical trials to safely provide menopausal women with relief from hot flashes.